Outcome of Board Meeting held on 06th May 2026 as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kabra Drugs Ltd's board approved two major strategic initiatives: (1) expansion of pharmaceutical business through launch of own generic branded formulations via channel partners under 'Mr. Franchise', starting with South India before expanding nationwide; (2) entry into defence manufacturing with AI integration, including seeking SCOMET License from DGFT and establishing an AI & Defence Technology R&D facility at Cactus TECCI Park in Chennai. The company also appointed Mr. Alagiamanavalan as Independent Consultant for defence projects and revised postal ballot dates due to administrative issues.
The pharmaceutical expansion could drive revenue growth in high-growth therapeutic markets, while the defence & AI pivot represents a significant strategic diversification with potential for higher-margin business, though SCOMET License approval and actual order flow remain pending.